Abstract. D-allose is a rare sugar which has been shown to have growth inhibitory effects in several kinds of malignancies. However, the effect of D-allose on lung cancer progression has not been previously studied. To investigate the antitumour effect of D-allose in lung cancer cells and its mechanism, human non-small cell lung cancer (NSCLC) cell lines (squamous cell carcinomas: EBC1 and VMRC-LCD; adenocarcinomas: A549, HI1017, RERF-LC-A1 and NCI-H1975) were treated with D-allose (50 mM) with or without cisplatin (5 µM). D-allose inhibited cell growth, particularly in EBC1 and VMRC-LCD cells. In combination with cisplatin, D-allose had a synergistic growth inhibitory effect. D-allose increased the expression of thioredoxin interacting protein (TXNIP) at mRNA and protein levels. D-allose decreased the proportion of cells in G1 phase and increased those in S and G2/M phases. For in vivo experiments, EBC1 cells were inoculated into BALB/c-nu mice. After tumourogenesis, D-allose and cisplatin were injected. In this mouse xenograft model, additional treatment with D-allose showed a significantly greater tumour inhibitory effect compared with cisplatin alone, accompanied by lower Ki-67 and higher TXNIP expression. In conclusion, D-allose inhibited NSCLC cell proliferation in vitro and tumour progression in vivo. In combination with cisplatin, D-allose had an additional antitumour effect. Specifically, increased TXNIP expression and subsequent G2/M arrest play a role in D-allose-mediated antitumour effects in NSCLC.

Introduction

D-allose is a rare sugar that is found only in very small quantities in nature. However, the discovery of D-tagatose 3-epimerase, an enzyme that can convert D-fructose to D-allulose (psicose) enabled the bioproduction on a large scale of all rare sugars including D-allose as shown by the ring form structure named ‘Izumoring’ (1,2).

Recent studies have shown that D-allose has growth inhibitory effects in several kinds of malignancies including hepatocellular carcinoma, prostate, ovarian, and head and neck cancers, and leukaemia (3-9). However, the effect of D-allose on lung cancer progression has not been studied.

Thioredoxins, a small molecular weight protein, is a potent protein disulphide oxidoreductase that functions as a potent antioxidant (10,11). Protein disulphide targets for reduction by thioredoxin include many transcription factors involved in cell activation and proliferation such as p53, nuclear factor-κB, and AP-1 (10,11). Some studies have shown that the expression of thioredoxin is associated with growth and differentiation of non-small cell lung cancer (NSCLC) (12-15). Serum thioredoxin levels were higher in NSCLC patients than in controls (15). The expression of thioredoxin is also associated with lymph node metastasis and poor prognosis in patients with operable NSCLC (10).

Thioredoxin interacting protein (TXNIP), also known as vitamin D3 upregulated protein 1 (16) or thioredoxin-binding protein-2 (17), interacts with thioredoxin and serves as a negative regulator of its biological function (17). TXNIP mediates cell cycle arrest and acts as a tumour suppressor (18,19). Notably, TXNIP deficiency initiated hepatocellular carcinogenesis in transgenic mice (20). In addition, recent reports have shown that D-allose stimulates the expression of TXNIP in several kinds of malignancy (7,9,21,22).

Based on this background, we investigated the antitumour effect of D-allose in lung cancer cells in combination with cisplatin, one of the most readily available anticancer drugs for lung cancer, and its effect on TXNIP expression.

Materials and methods

Reagents. Sugars used in this study, including D-glucose, D-allose, and D-allulose (also called D-psicose), were supplied...
by the Rare Sugars Research Centre, Kagawa University (Kagawa, Japan). Antibodies used were anti-β-actin (#A2228; Sigma-Aldrich, St. Louis, MO, USA), anti-thioredoxin (#2429; Cell Signaling Technology, Inc., Beverly, MA, USA) and anti-TXNIP (#K0205-3; MBL, Nagoya, Japan, and #HPA031085; Sigma-Aldrich). Cisplatin was purchased from Wako Pure Chemical Industries, Ltd. (Kanagawa, Japan).

Cell culture. Human NSCLC cell lines (squamous cell carcinomas: EBC1 and VMRC-LCD; adenocarcinomas: A549, H11017 and RERF-LC-A1) were obtained from the Japan Cancer Research Bank (Tokyo, Japan). NCI-H1975 (adenocarcinoma) cells were obtained from American Culture Collection (Manassas, VA, USA). NSCLC cells were cultured in RPMI-1640 supplemented with 10% foetal bovine serum (FBS).

Lung cancer cell viability. Lung cancer cell viability was assessed by WST-1 assay. Briefly, cells were incubated in RPMI-1640 with 10% FBS and 10% WST-1 reagent (Roche Applied Science, Mannheim, Germany). After incubation for 4 h, 100 μl of sample was transferred to a 96-well plate and the absorbance at 450 nm was measured with a microplate reader (iMark™; Bio-Rad, Hercules, CA, USA). All samples were assessed at least triplicate.

Animals and xenotransplantation. BALB/c-nu mice female were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan) and maintained in the Division of Animal Experiments, Life Science Research Center, Kagawa University according to the Institutional Regulations for Animal Experiments. The protocols for the animal experiments were approved by the Animal Care and Use Committee for Kagawa University (the ethical permit no. 15161). Briefly, 10^6 EBC1 cells were subcutaneously inoculated into 48 six-week-old mice. Two weeks later, tumourigenesis was observed. Subsequently, cisplatin (3 mg/kg, 100 μl in PBS) was injected intraperitoneally for 3 weeks (once a week) and D-allose (500 mM, 100 μl in PBS) was injected around the tumour for 3 weeks (five days per week). Only PBS was injected as controls. Twelve mice were assessed in each group. Tumour sizes were measured every week with a calliper. The tumour volume (TV) was calculated using the formula TV = ½ x A x B2 (where A = length in millimetres and B = width in millimetres) in accordance with previous studies (23). Mice were monitored for up to 8 weeks after inoculation then euthanized.

Histology and immunohistochemistry. The engrafted tumours were fixed and tissue sections were immunohistochemically examined using Vectastain ABC rabbit IgG kit (Vector Laboratories, Burlingame CA, USA) using an anti-TXNIP antibody (#HPA031085; Sigma-Aldrich). Immunostaining for Ki-67 was performed at Shikoku Cytopathological Laboratory (Kagawa, Japan) using an anti-Ki-67 antibody (Dako, Glostrup, Germany). For subsequent procedures, a BOND automatic detection system (Leica Biosystems, Bannockburn, IL, USA) was used. Five samples per condition were evaluated, and the percentage of tumour cells expressing TXNIP or Ki-67 was assessed.

Western blotting. After sugar treatment for three days, cells were scraped into lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, and 0.5% NP40) with protease inhibitors (Sigma-Aldrich) and treated with sonication. Samples were centrifuged for 5 min at 14,000 rpm and the supernatants were collected. For western blot analysis, 20 μg proteins were separated in 10% SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and blocked with 5% (w/v) non-fat dried milk in TTBS. The membrane was incubated with anti-TXNIP (MBL, 1:2,000), anti-thioredoxin (1:1,000) or anti-β-actin (1:5,000) antibodies, and then incubated with a horseradish peroxidase-conjugated anti-mouse IgG (Cell Signalling Technology, Inc.). Signals were detected with Immobilon Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA).

Real-time quantitative PCR. Cells were cultured in a 60-mm dish and 50 mM of various sugars were added to the medium and further incubated for three days. Total RNA was purified with an RNeasy Mini kit (Qiagen, Hilden, Germany), and used to synthesize cDNAs with an Omniscript RT kit (Qiagen) and random hexamers (Takara Bio Inc., Shiga, Japan). Real-time quantitative PCR was carried out using Probe qPCR mix (Takara Bio Inc.), TaqMan gene expression assay primers (Applied Biosystems, Waltham, MA, USA), and a 7300 real-time PCR system (Applied Biosystems). Primers used were purchased from Applied Biosystems (TaqMan primers; TXNIP: Hs01006897_g1, thioredoxin: Hs01555214_g1, GAPDH: Hs02758991_g1). PCR amplifications comprised 40 cycles of denaturation at 95˚C for 10 sec, annealing and elongation at 60˚C for 30 sec. Each reaction was performed in duplicate. GAPDH gene expression was used as an internal control and the threshold value (Ct) for each sample was used to determine the expression level of the gene.

Profiling of DNA content by flow cytometry. Profiling of DNA content was performed as previously reported (24). Briefly, cells were treated with sugars (50 mM) or cisplatin (5 μM) for 24 h and then fixed with cold 70% ethanol in PBS for 30 min at 4˚C. Cells were then pelleted by centrifugation and resuspended in the staining solution (50 μg propidium iodide, 100 μg RNase A in 1 ml PBS). After 1-h incubation at 4˚C, the DNA content profile was assessed by flow cytometry.

Statistical analysis. Each experiment was repeated at least three times. Student’s t-test was used to compare data between two groups. Data are expressed as the means ± SE. P-values of <0.05 were considered as statistically significant. All statistical analyses were conducted using Excel 2013 (Microsoft Corp., Redmond, WA, USA).

Results

D-allose inhibits the proliferation of lung cancer cells. NSCLC cell lines were cultured in regular medium with either D-glucose, D-allose, or D-allulose. The proliferation of EBC1 cells, a squamous cell lung cancer cell line, was inhibited by D-allose in a dose- and time-dependent manner (Fig. 1A and B). Similarly, proliferation of another squamous cell lung cancer cell line, VMRC-LCD, was also inhibited by...
D-allose (Fig. 1C). However, the cell growth inhibitory effect of D-allose was very small or no difference was observed compared with that of D-glucose in other cell lines tested (adenocarcinomas: A549, HI1017, H1975 and RERF-LC-A1 cells, Fig. 1D). Cisplatin inhibited cell proliferation (viability) in both EBC1 and VMRC-LCD cell lines (Fig. 2). In combination with D-allose, but not D-glucose or D-allulose, cell proliferation (viability) was further inhibited (Fig. 2).

D-allose stimulates the expression of TXNIP and modifies the DNA content profile. The expression of TXNIP increased in response to D-allose, but not to other sugars, in both EBC1 and VMRC-LCD cells (Fig. 3). This was confirmed by both western blotting (Fig. 3A) and real-time PCR (Fig. 3B and C). Although TXNIP mRNA expression was also increased by cisplatin in EBC1 cells, this was not statistically significant (Fig. 3B). On the other hand, no obvious changes in expressions of thioredoxin were observed in response to D-allose (Fig. 3D-F). To investigate modulation of cell cycles, DNA content profiling was assessed (Fig. 4). After D-allose treatment, the percentage of cells in G1 phase of the cell cycle moderately decreased, while that in S and G2/M phases increased. In contrast, cisplatin induced significant mid-S-phase accumulation and reduction in G2/M phases.

D-allose inhibits the tumour progression in mouse xenografts. EBC1 cells were subcutaneously inoculated into BALB/c-nu mice and after tumour development, D-allose and cisplatin were injected as described in Materials and methods. Both D-allose and cisplatin inhibited tumour progression compared

Figure 1. Effect of sugars on proliferation of lung cancer cells. Lung cancer cell lines were cultured in RPMI-1640 with either D-glucose, D-allose, or D-allulose. The medium was replaced every two days, and cell numbers were counted. (A) EBC1 cells were cultured for six days with various concentrations of sugars and cell numbers were counted, (B) Time course of EBC1 cell proliferation with 50 mM of sugars. (C) Time course of VMRC-LCD cell proliferation with 50 mM of sugars. (D) Lung adenocarcinoma cell lines (A549, HI1017, H1975 and RERF-LC-A1 cells) were cultured with 50 mM of sugars for six days and cell numbers were counted. *P<0.01 compared with those cultured without sugars and #P<0.01 compared with those cultured with D-glucose.

Figure 2. Combination of D-allose and cisplatin on cell proliferation. (A) EBC1 and (B) VMRC-LCD cells were cultured with sugars (50 mM) and/or cisplatin (5 µM). After three days, cell proliferation (viability) was assessed by WST-1 assay. *P<0.01 compared with those cultured without sugars and #P<0.01 compared with those cultured with D-glucose at the same cisplatin status.
With the control (PBS alone) (Fig. 5A). Combined treatment with D-allose and cisplatin resulted in a significant reduction in tumour volumes compared with cisplatin alone (Fig. 5A). No obvious side effect such as body weight loss was observed in the D-allose group, while treatment with cisplatin resulted in body weight loss slightly but significantly (Fig. 5B). Consistent with reduced tumour volumes, the Ki-67 index was lower in the D-allose plus cisplatin group compared with cisplatin alone (Fig. 5C). Similar to the in vitro experiments, higher levels of TXNIP expression were observed in the D-allose plus cisplatin group compared with cisplatin alone (Fig. 5D).

**Discussion**

In the present study, D-allose inhibited NSCLC cell proliferation and tumour progression. Supplementary D-allose treatment resulted in stronger antitumour effect than cisplatin
Figure 4. Profiling of DNA contents. EBC1 cells were treated with sugars (50 mM) or cisplatin (5 µM) for 24 h. Cells were harvested and the DNA content profile was assessed by flow cytometry. (A) Values are the means of three separate experiments. *P<0.05, **P<0.01 compared with control. (B) Representative histograms for each condition.

Figure 5. Tumour progression in mouse xenografts. One million EBC1 cells were inoculated subcutaneously per BALB/c-nu mouse. Two weeks after inoculation, tumourigenesis was observed. Subsequently, cisplatin (3 mg/kg) was injected intraperitoneally for 3 weeks (once a week) and D-allose (500 mM) was injected around the tumour for 3 weeks (five days per week). Tumour size was measured up to 8 weeks after inoculation of cells, and then mice were euthanized. Twelve tumours (mice) were assessed in each group. (A) Time course of the tumour size. *P<0.01 compared with conditions without cisplatin and **P<0.01 compared with conditions with cisplatin only. (B) Body weight of mice at 8 weeks. *P<0.05 compared with the group without cisplatin. (C) Ki-67 index in tumour tissues. Five tumours (mice) were assessed per group. *P<0.05 compared with the group with cisplatin only. Scale bars, 50 µm. (D) Immunostaining for TXNIP in tumour tissues. *P<0.05 compared with the group with cisplatin only. Scale bars, 50 µm. TXNIP, thioredoxin interacting protein.
alone. D-allose worked differently from cisplatin on NSCLC cells and markedly stimulated TXNIP expression, a tumour suppressor gene product, to inhibit cell proliferation, which might be a mechanism of the antitumour effect.

The growth inhibitory effect of D-allose was more significant in squamous cell carcinoma (EBC1 and VMRC-LCD) than in adenocarcinoma (A549, H1107, H1975 and RERF-LC-A1) cell lines. Thus, there might be a difference in the response to D-allose between squamous cell carcinoma and adenocarcinoma. In the last two decades, several novel therapeutic options have been newly developed for lung adenocarcinoma, including pemetrexed (an anticancer drug), bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor), and several tyrosine kinase inhibitors for epidermal growth factor receptor and anaplastic lymphoma kinase. These drugs are usually unavailable for squamous cell carcinoma because of their ineffectiveness and adverse events. Although the anticancer effect of D-allose itself might be small for NSCLC, it demonstrates additional potential in combination with cytotoxic agents such as cisplatin. Thus, D-allose might be a new supplemental treatment for lung cancer, particularly for squamous cell carcinoma.

Some evidence has shown that antioxidants protect and stimulate the growth of established tumours (25-27). A large epidemiologic study has shown a higher incidence of lung cancer in men who received β-carotene, a representative antioxidant, than in those who did not (25). A review report concluded that the intake of supplemental antioxidants during chemotherapy and radiotherapy should be discouraged because of the possibility of tumour protection and reduced survival (26). In addition, the antioxidants N-acetylcysteine and vitamin E accelerated lung cancer progression and reduced survival in mouse models (27). These findings suggest that antioxidants protect tumour cells as well as healthy cells from oxidative damage and accelerate cell proliferation of early cancers or tumourigenesis of precancerous lesions (27). In a view of the redox status, D-allose stimulates TXNIP, which might result in increased antitumour activity in NSCLC.

Several concrete mechanisms for the antitumour effect of D-allose have been reported. First, D-allose modulates cell cycle regulatory proteins and induces G2/M cell cycle arrest (7). Consistent with this report, D-allose treatment resulted in accumulation in G2/M phases in the present study. Low Ki-67 index in the in vivo experiment is also consistent with this G2/M cell cycle arrest. Another study reported that D-allose induces upregulation of TXNIP and subsequent G1 cell cycle arrest (21). Thioredoxin is an important regulator of the cell cycle in the G1 phase via cyclin D1 transcription and the ERK/AP-1 signalling pathways (28). Regarding the growth inhibitory effect of D-allose, it has been reported that the nuclear localization and stabilization of p27kip1 increases in cyclin-dependent kinase (CDK) 2 and CDK inhibitor 2B, and decrease in FK506 binding protein 12-rapamycin-associated protein 1 have roles (21). Second, upregulation of TXNIP and inhibition of thioredoxin by D-allose can induce the generation of reactive oxygen species, resulting in DNA damage in cells and antitumour effects (7). Third, apoptosis could be induced by D-allose (7), however, apoptosis may not appear in all types of cells (3). Fourth, D-allose can inhibit glucose transporter expression and glucose uptake in several human cancer cell lines (9). Some of the above mechanisms of the antitumour effect of D-allose could be associated with regulating expression of thioredoxin and TXNIP, that is, redox status in the broader sense.

In cell cycle analyses, cisplatin significantly induced mid-S-phase accumulation, which is consistent with a previous report (29). Because the modulation pattern in cell cycles is different between cisplatin and D-allose, the combination of these two agents may have additional antitumour potential compared with each agent by itself. Cisplatin showed a tendency to increase the expression of TXNIP although no statistical significance was observed. In this regard, several studies have investigated the effect of anticancer drugs on the expression of TXNIP (3,7,30). 5-Fluorouracil stimulated TXNIP expression in hepatocellular carcinoma and colon cancer cells, suggesting the mechanism of cytotoxicity of this drug (3,30). In contrast, docetaxel had no effect on TXNIP expression in head and neck cancer cells (7). Thus, the anticancer drugs seem to vary in their influence on TXNIP expression depending upon their mechanism of action.

Several studies have reported the clinical significance of thioredoxin and TXNIP in NSCLC from other viewpoints. Thioredoxin takes part in the activation of transcription factors and regulates differentiation as well as cell growth (14). In high-grade tumours, thioredoxin expression is diminished, suggesting loss of redox regulation in tumours with low differentiation (14). In addition, it has been reported that patients with high TXNIP expression demonstrated a significantly shorter progression-free survival compared with those with low TXNIP expression (31). The expression of TXNIP could also be affected by many factors including tumour environment (31). In the present study, no obvious change in thioredoxin expression was observed in response to D-allose. In this regard, thioredoxin expression itself may not always change because TXNIP binds thioredoxin, and thioredoxin activity may be more important. The clinical significance of the expression and activity of thioredoxin and TXNIP in patients with NSCLC should be investigated in greater detail.

Because most cell types express glucose transporters, D-allose may affect cell growth in normal cells as well as cancer cells. However, interestingly, it has been reported that no growth inhibitory or cytotoxic effects of D-allose were observed in normal hepatocytes (21). In addition, D-allose inhibited GLUT1 expression (9). In the present study, D-allose had no obvious unfavourable side effect in the mouse xenograft model, which is an advantage in clinical use. We also injected D-allose subcutaneously directly around the developed tumour. However, it is technically difficult to inject around tumours developed inside the lung. For the clinical use of D-allose, another drug delivery route such as oral ingestion or intravenous administration should be developed.

In conclusion, D-allose inhibited NSCLC cell proliferation in vitro and tumour progression in vivo. In combination with cisplatin, D-allose had an additive antitumour effect. Specifically, increased TXNIP expression and subsequent G2/M arrest play a role in D-allose-mediated antitumour effects in NSCLC.
Acknowledgements

The authors would like to thank Ms. Takimi Tamaki for her support. This study was supported by the Rare Sugar Research
grant funded by Kagawa Prefecture.

References


